<DOC>
	<DOCNO>NCT01311648</DOCNO>
	<brief_summary>The objective study demonstrate safety efficacy treatment BAY81-8973 prophylaxis breakthrough bleeds child severe haemophilia A .</brief_summary>
	<brief_title>BAY81-8973 Pediatric Safety Efficacy Trial</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , age &lt; /= 12 year Severe hemophilia A define &lt; 1 % FVIII : C PTPs ( previously treat patient ) &gt; 50 Exposure day ( ED ) high purity FVIII , PUPs ( previously untreated patient ) prior exposure high purity FVIII MTPs ( minimally treat patient ) previously receive 3 injection FVIII concentrate No current evidence history inhibitory antibody History FVIII inhibitor formation Diagnosed bleed disorder Platelet count &lt; 100000 cells/Î¼L Kidney liver dysfunction Known hypersensitivity FVIII</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recombinant factor VIII</keyword>
	<keyword>pediatric use</keyword>
</DOC>